At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 517 enrolled
Drug / intervention
Brolucizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)
In Brief
A Phase 3 clinical trial evaluating Brolucizumab and Aflibercept for Diabetic Macular Edema. Completed, enrolled 517 participants across 92 sites in 5 countries.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesHungary, Israel, Puerto Rico, Slovakia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJul 2019
Primary CompletionMar 2021
TodayJul 2026
First PostedApr 17, 2019
Enrollment StartJul 17, 2019
Primary CompletionMar 24, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.2 years ago
Interventions
Brolucizumabdrug
Intravitreal injection
Afliberceptdrug
Intravitreal injection